Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2011-11-04 16:42:41
Reporting Period:
Filing Date:
Accepted Time:
2011-11-04 16:42:41
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1333248 Cadence Pharmaceuticals Inc CADX Pharmaceutical Preparations (2834) 000000000
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1244823 B James Breitmeyer C/o Cadence Pharmaceuticals, Inc.
12481 High Bluff Drive, Suite 200
San Diego CA 92130
Evp, Cmo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-11-02 12,500 $0.00 22,500 No 4 M Direct
Common Stock Disposition 2011-11-03 12,500 $5.70 10,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2011-11-02 12,500 $0.00 12,500 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
  1. Each restricted stock unit represented the right to receive one share of common stock on the earlier of (a) the one-year anniversary of FDA approval of the Company's NDA for intravenous acetaminophen, and (b) immediately prior to the consummation of a change in control of the Company, subject to the recipient's continued status as an employee, independent director or consultant of the Company or any subsidiary on the applicable vesting date. The Company received FDA approval of its NDA for intravenous acetaminophen on November 2, 2010.
  2. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2011.
  3. This transaction was executed in multiple trades at prices ranging from a low of $5.65 to a high of $5.76. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.